Sphingoid long chain bases prevent lung infection by Pseudomonas aeruginosa

EMBO Molecular Medicine

Volumn 6, Issue 9, 2014, Pages 1205-1214

  Pewzner Jung, Yael ^a   Tavakoli Tabazavareh, Shaghayegh ^b   Grassmé, Heike ^b   Becker, Katrin Anne ^b   Japtok, Lukasz ^c   Steinmann, Jörg ^b   Joseph, Tammar ^a   Lang, Stephan ^b   Tuemmler, Burkhard ^d   Schuchman, Edward H ^e   Lentsch, Alex B ^f   Kleuser, Burkhard ^c   Edwards, Michael J ^f   Futerman, Anthony H ^a   Gulbins, Erich ^b,f  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF POTSDAM   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Pseudomonas aeruginosa; Cystic fibrosis; Long chain base; Lung infection; Sphingosine

Indexed keywords

ACID CERAMIDASE; CERAMIDE; FINGOLIMOD; SPHINGOLIPID; SPHINGOSINE; PROPANEDIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHUS; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; INFECTION PREVENTION; INFECTION SENSITIVITY; LUNG FIBROSIS; MALE; MOUSE; NONHUMAN; PSEUDOMONAS AERUGINOSA; RESPIRATORY EPITHELIUM; TRACHEA; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; COMPLICATION; CYSTIC FIBROSIS; DISEASE PREDISPOSITION; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; TRANSGENIC MOUSE;

ACID CERAMIDASE; ADMINISTRATION, INHALATION; ANIMALS; CERAMIDES; CYSTIC FIBROSIS; DISEASE SUSCEPTIBILITY; HUMANS; MICE, INBRED C57BL; MICE, TRANSGENIC; PROPYLENE GLYCOLS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; SPHINGOSINE; TRACHEA;

EID: 84916929004     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201404075     Document Type: Article

References (25)

1. Arikawa J, Ishibashi M, Kawashima M, Takagi Y, Ichikawa Y, Imokawa G (2002) Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus. J Invest Dermatol 119: 433-439
2. Barasch J, Kiss B, Prince A, Saiman L, Gruenert D, al-Awqati Q (1991) Defective acidification of intracellular organelles in cystic fibrosis. Nature 352: 70-73
3. Becker KA, Riethmüller J, Lüth A, Döring G, Kleuser B, Gulbins E (2010) Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am J Respir Cell Mol Biol 42: 716-724
4. Bibel DJ, Aly R, Shinefield HR (1992) Antimicrobial activity of sphingosines. J Invest Dermatol 98: 269-273
5. Bodas M, Min T, Mazur S, Vij N (2011) Critical modifier role of membrane-cystic fibrosis transmembrane conductance regulator-dependent ceramide signaling in lung injury and emphysema. J Immunol 186: 602-613
6. Brodlie M, McKean MC, Johnson GE, Gray J, Fisher AJ, Corris PA, Lordan JL, Ward C (2010) Ceramide is increased in the lower airway epithelium of people with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med 182: 369-375
7. Charizopoulou N, Wilke M, Dorsch M, Bot A, Jorna H, Jansen S, Stanke F, Hedrich HJ, de Jonge HR, Tümmler B (2006) Spontaneous rescue from cystic fibrosis in a mouse model. BMC Genet 7: 18
8. Cox AD, Wilkinson SG (1991) Ionizing groups in lipopolysaccharides of Pseudomonas cepacia in relation to antibiotic resistance. Mol Microbiol 5: 641-646
9. Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV (1996) Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 109: 1019-1029
10. Cystic Fibrosis Foundation (2011) 2011 Patient Registry Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation
11. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PTPNational Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group (2006) A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354: 229-240
12. Fayyaz S, Henkel J, Japtok L, Krämer S, Damm G, Seehofer D, Püschel GP, Kleuser B (2014) Involvement of sphingosine 1-phosphate in palmitate-induced resistance of hepatocytes via the S1P2 receptor subtype. Diabetologia 57: 373-382
13. Fischer CL, Drake DR, Dawson DV, Blanchette DR, Brogden KA, Wertz PW (2012) Antibacterial activity of sphingoid bases and fatty acids against Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 56: 1157-1161
14. Fischer CL, Walters KS, Drake DR, Blanchette DR, Dawson DV, Brogden KA, Wertz PW (2013) Sphingoid bases are taken up by Escherichia coli and Staphylococcus aureus and induce ultrastructural damage. Skin Pharmacol Physiol 26: 36-44
15. LaBauve AE, Wargo MJ (2014) Detection of host-derived sphingosine by Pseudomonas aeruginosa is important for survival in the murine lung. PLoS Pathog 10: e1003889
16. Li CM, Hong SB, Kopal G, He X, Linke T, Hou WS, Koch J, Gatt S, Sandhoff K, Schuchman EH (1998) Cloning and characterization of the full-length cDNA and genomic sequences encoding murine acid ceramidase. Genomics 50: 267-274
17. McManus AT, Mason AD, McManus WF, Pruitt BA (1985) Twenty-five year review of Pseudomonas aeruginosa bacteremia in a burn center. Eur J Clin Microbiol 4: 219-223
18. Pewzner-Jung Y, Park H, Laviad EL, Silva LC, Lahiri S, Stiban J, Erez-Roman R, Brügger B, Sachsenheimer T, Wieland F et al (2010) A critical role for ceramide synthase 2 in liver homeostasis: I. alterations in lipid metabolic pathways. J Biol Chem 285: 10902-10910
19. Pezzulo AA, Tang XX, Hoegger MJ, Alaiwa MHA, Ramachandran S, Moninger TO, Karp PH, Wohlford-Lenane CL, Haagsman HP, van Eijk M et al (2012) Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 487: 109-113
20. Pruett ST, Bushnev A, Hagedorn K, Adiga M, Haynes CA, Sullards MC, Liotta DC, Merrill AH (2008) Biodiversity of sphingoid bases ('sphingosines') and related amino alcohols. J Lipid Res 49: 1621-1639
21. Rakhimova E, Wiehlmann L, Brauer AL, Sethi S, Murphy TF, Tümmler B (2009) Pseudomonas aeruginosa population biology in chronic obstructive pulmonary disease. J Infect Dis 200: 1928-1935
22. Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, De Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kürthy G, Schmid KW et al (2008) Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 14: 382-391
23. Ulrich M, Worlitzsch D, Viglio S, Siegmann N, Iadarola P, Shute JK, Geiser M, Pier GB, Friedel G, Barr ML et al (2010) Alveolar inflammation in cystic fibrosis. J Cyst Fibros 9: 217-227
24. Vidal F, Mensa J, Almela M, Martínez JA, Marco F, Casals C, Gatell JM, Soriano E, Jimenez de Anta MT (1996) Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 156: 2121-2126
25. Xu M, Xia M, Li X-X, Han W-Q, Boini KM, Zhang F, Zhang Y, Ritter JK, Li P-L (2012) Requirement of translocated lysosomal V1 H(+)-ATPase for activation of membrane acid sphingomyelinase and raft clustering in coronary endothelial cells. Mol Biol Cell 23: 1546-1557